Growth hormone decline after 40: what is actually happening and why

You are not imagining it. Recovery takes longer than it did at 34. Body composition shifts even when your training and diet have not changed. Sleep feels less restorative. These are not motivational failures. They have a measurable physiological basis, and growth hormone decline is a significant part of that story.

This post covers the mechanism behind age-related growth hormone decline, what the research actually shows, and where the evidence is still limited. No exaggeration in either direction.

The physiology: why growth hormone output drops with age

Growth hormone (GH) is produced by the anterior pituitary gland, but the pituitary does not act alone. It responds to two upstream signals from the hypothalamus: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which suppresses it. The balance between these two signals determines how much GH you produce.

GH is not released continuously. It comes out in pulses, most of them during slow-wave (deep) sleep. The largest pulse of the day typically occurs in the first few hours after you fall asleep. Each pulse triggers the liver to produce insulin-like growth factor 1 (IGF-1), which is the downstream mediator responsible for most of the tissue-level effects attributed to GH, including muscle protein synthesis, fat metabolism, and cellular repair.

Starting in your late twenties, total daily GH output begins falling at roughly 14 to 15 percent per decade. By the time you are in your mid-forties, pulsatile GH secretion has declined significantly compared to young adulthood. The primary driver is not a failing pituitary. The gland itself retains capacity to release GH when properly stimulated. The problem is upstream: the hypothalamus produces less GHRH relative to somatostatin as you age, which means the pituitary receives fewer and weaker release signals.

This distinction matters clinically. It is the reason GHRH-based therapies like sermorelin work by restoring a physiological signal rather than bypassing the system entirely. The axis is still functional. It is underdriven.

What the research shows, and where it is honest about limits

The foundational human study most often cited in this space is Khorram et al. (1997, PMID 9141536). Researchers administered GHRH to older adults over six months and measured changes in IGF-1 levels, body composition, immune markers, and sleep architecture. They observed increases in IGF-1 and improvements in slow-wave sleep quality, along with modest favorable changes in lean mass and fat mass. The mechanism held up: GHRH administration restored downstream signaling through an intact pituitary-liver axis.

Walker et al. (2006, PMC2699646) added an important layer. This research examined the relationship between slow-wave sleep and GH secretion, confirming that deep sleep is not just a consequence of GH release, it is also a driver of it. The relationship is bidirectional. Disrupted sleep reduces GH output; blunted GH signaling appears to reduce sleep quality. This creates a cycle that compounds with age.

It is worth being direct about the limitations of this evidence base. The Khorram trial had a small sample size. Most GHRH research involves older populations, not men in their forties who are still training at a high level. Long-term data beyond twelve months is sparse. And separating the effects of restored GH signaling from confounding factors like sleep improvement is methodologically difficult. The research is real and relevant, but it does not support overconfident claims about outcomes.

• The pituitary gland retains GH-releasing capacity well into middle age; the upstream GHRH signal is what weakens.
• Age-related GH decline runs approximately 14 to 15 percent per decade beginning in your late twenties.
• IGF-1 is the main downstream marker of GH activity and the one most commonly measured in clinical monitoring.
• Slow-wave sleep and GH secretion are bidirectionally linked, meaning poor sleep compounds hormonal decline.
• GHRH analogs like sermorelin work by restoring a physiological signal to the pituitary, not by injecting GH directly.
• Human trials on GHRH in aging adults are real but small, and most are more than fifteen years old.

Why this matters at 44 specifically

At 44, you are likely past the steepest part of the decline curve but not at the floor. That means there is still meaningful GH pulsatility to work with, and the axis is still responsive to stimulation. This is different from trying to restore a system that has shut down entirely.

The practical consequences of blunted GH signaling at your training level are worth naming precisely. GH plays a direct role in lipolysis, the breakdown of stored fat for fuel, particularly visceral fat. It supports collagen synthesis, which matters for tendon and connective tissue recovery. It facilitates nitrogen retention during muscle repair after resistance training. And as the Walker research highlights, its relationship with deep sleep means that suboptimal GH output may be degrading the recovery quality you are counting on from your seven hours.

None of this means GH decline is the only variable in what you are experiencing. Testosterone, cortisol rhythm, thyroid function, training load, and nutritional periodization all interact. GH is one axis among several. But it is a well-characterized one with a clear mechanism, and it is the axis where your lifestyle behaviors, sleep, fasting intervals, high-intensity training, have the most leverage outside of pharmacological support.

Where sermorelin fits into this picture

Sermorelin is a synthetic analog of GHRH. It is the first 29 amino acids of the native GHRH peptide, which is sufficient to bind the GHRH receptor on pituitary somatotroph cells and stimulate GH release. Because it works through the pituitary rather than delivering exogenous GH, the pulsatile pattern of GH secretion is preserved, and the feedback loop that prevents excessive GH levels remains intact. Somatostatin still acts as a brake.

This matters for safety and for physiological appropriateness. Direct GH administration bypasses the pituitary entirely and can suppress the axis over time. Sermorelin works with the existing architecture. The pituitary releases GH in response to the signal; IGF-1 rises; the hypothalamus reads that rise and modulates its output accordingly. The system self-regulates.

Compounded sermorelin is typically administered subcutaneously, most often at bedtime to align with the natural nocturnal GH pulse. Dosing and monitoring are individualized. IGF-1 is the primary lab marker used to assess response. A provider should review your baseline, your goals, and your health history before determining whether this approach is appropriate for you.

If you have done the research and want a clinical conversation rather than a sales pitch, StaveMD is structured around that interaction. Providers review your intake, ask the questions that matter, and give you a straight answer on whether sermorelin is a reasonable option given your specific situation.